The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

Antonio Russo, Lorena Incorvaia, Ettore Capoluongo, Pierosandro Tagliaferri, Antonio Galvano, Marzia Del Re, Umberto Malapelle, Rita Chiari, Pierfranco Conte, Romano Danesi, Matteo Fassan, Roberto Ferrara, Maurizio Genuardi, Paola Ghiorzo, Stefania Gori, Fiorella Guadagni, Antonio Marchetti, Paolo Marchetti, Massimo Midiri, Nicola NormannoFrancesco Passiglia, Carmine Pinto, Nicola Silvestris, Giovanni Tallini, Simona Vatrano, Bruno Vincenzi, Saverio Cinieri, Giordano Beretta

Research output: Contribution to journalReview articlepeer-review

Abstract

The development of innovative technologies and the advances in the genetics and genomics, have offered new opportunities for personalized treatment in oncology. Although the selection of the patient based on the molecular characteristics of the neoplasm has the potential to revolutionize the therapeutic scenario of oncology, this approach is extremely challenging. The access, homogeneity, and economic sustainability of the required genomic tests should be warranted in the clinical practice, as well as the specific scientific and clinical expertise for the choice of medical therapies. All these elements make essential the collaboration of different specialists within the Molecular Tumor Boards (MTBs). In this position paper, based on experts’ opinion, the AIOM-SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies critically discuss the available molecular profiling technologies, the proposed criteria for the selection of patients candidate for evaluation by the MTB, the criteria for the selection and analysis of biological samples, and the regulatory and pharmaco-economic issues.

Original languageEnglish
Article number103567
JournalCritical Reviews in Oncology/Hematology
Volume169
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Molecular profiling
  • Molecular tumor board
  • Mutational oncology
  • Precision oncology

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies'. Together they form a unique fingerprint.

Cite this